The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
Body weight between 40 kg and 100 kg inclusive at screening and upon initial confinement.
BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exposure to any anti-interleukin-12/23 or anti interleukin-23 treatment for at least one year prior to Screening.
Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of first dose of study treatment or during the study.
Parallel
Risankizumab
DrugIntravenous (IV)
Risankizumab
DrugSubcutaneous (SC) Injections
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Maximum Observed Serum Concentration (Cmax) of Risankizumab
Cmax of Risankizumab.
Time to Cmax (Tmax) of Risankizumab
Tmax of Risankizumab.
Area Under the Serum Concentration-Time Curve (AUC) of Risankizumab
AUCt of Risankizumab.
